Cell cycle control in the kidney

Nephrology Dialysis Transplantation

Volumn 30, Issue 10, 2015, Pages 1622-1630

  Thomasova, Dana ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

acute kidney injury; chronic kidney disease; crescent; renal fibrosis; renal function

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; RAPAMYCIN; ROSCOVITINE; CELL CYCLE PROTEIN;

ACUTE KIDNEY FAILURE; ANTIPROLIFERATIVE ACTIVITY; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; CELL DIVISION; CELL PROLIFERATION; DNA DAMAGE; DRUG MECHANISM; GLOMERULONEPHRITIS; HOMEOSTASIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY; KIDNEY CELL; KIDNEY INJURY; KIDNEY TUBULE CELL; MESANGIUM CELL; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TISSUE REGENERATION; WOUND HEALING IMPAIRMENT; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; HUMANS; KIDNEY;

EID: 84943374240     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu395     Document Type: Review

References (64)

1. Kriz W, Lemley KV. A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol 2015; 26: 258-269
2. Lasagni L, Lazzeri E, Shankland SJ, et al. Podocyte mitosis-a catastrophe. Curr Mol Med 2013; 13: 13-23
3. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-120
4. Vitale I, Galluzzi L, Castedo M, et al. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12: 385-392
5. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008; 15: 1153-1162
6. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21: 245-255
7. Griffin SV, Pichler R, Dittrich M, et al. Cell cycle control in glomerular disease. Springer Semin Immunopathol 2003; 24: 441-457
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature, 2000; 408: 307-310
9. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501
10. Wu CF, Chiang WC, Lai CF, et al. Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol 2013; 182: 118-131
11. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604
12. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-344
13. Nadasdy T, Laszik Z, Blick KE, et al. Proliferative activity of intrinsic cell populations in the normal human kidney. J Am Soc Nephrol 1994; 4: 2032-2039
14. Nagata M, Nakayama K, Terada Y, et al. Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 1998; 153: 1511-1520
15. Barisoni L, Mokrzycki M, Sablay L, et al. Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 2000; 58: 137-143
16. Prescott LF. The normal urinary excretion rates of renal tubular cells, leucocytes and red blood cells. Clin Sci 1966; 31: 425-435
17. Canaud G, Bonventre JV. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant 2015; 30: 575-583
18. Shankland SJ, Wolf G. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol 2000; 278: F515-F529
19. Combs HL, Shankland SJ, Setzer SV, et al. Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Kidney Int 1998; 53: 892-896
20. Barisoni L, Kriz W, Mundel P, et al. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61
21. Barisoni L, Bruggeman LA, Mundel P, et al. HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 2000; 58: 173-181
22. Shankland SJ, Eitner F, Hudkins KL, et al. Differential expression of cyclindependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000; 58: 674-683
23. Liapis H, Romagnani P, Anders HJ. New insights into the pathology of podocyte loss: mitotic catastrophe. Am J Pathol 2013; 183: 1364-1374
24. Marshall CB, Krofft RD, Pippin JW, et al. CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo. Am J Physiol Renal Physiol 2010; 298: F1140-F1151
25. Hoshi S, Shu Y, Yoshida F, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35
26. Kuan CJ, al-Douahji M, Shankland SJ. The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 1998; 9: 986-993
27. Baba M, Wada J, Eguchi J, et al. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms. J Am Soc Nephrol 2005; 16: 3222-3234
28. Awazu M, Omori S, Ishikura K, et al. The lack of cyclin kinase inhibitor p27(Kip1) ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 2003; 14: 699-708
29. Mulay SR, Thomasova D, Ryu M, et al. Podocyte loss involves MDM2-driven mitotic catastrophe. J Pathol 2013; 230: 322-335
30. Schocklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int 1999; 56: 1199-1207
31. Pippin JW, Qu Q, Meijer L, et al. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997; 100: 2512-2520
32. Marshall CB, Shankland SJ. Cell cycle and glomerular disease: a minireview. Nephron Exp Nephrol 2006; 102: e39-e48
33. Cove-Smith A, Mulgrew CJ, Rudyk O, et al. Anti-proliferative actions of Ttype calcium channel inhibition in Thy1 nephritis. Am J Pathol 2013; 183: 391-401
34. Megyesi J, Udvarhelyi N, Safirstein RL, et al. The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure. Am J Physiol 1996; 271: F1211-F1216
35. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998; 101: 777-782
36. Price PM, Yu F, Kaldis P, et al. Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J Am Soc Nephrol 2006; 17: 2434-2442
37. DiRocco DP, Bisi J, Roberts P, et al. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol 2014; 306: F379-F388
38. Park SK, Kang MJ, Kim Wet al. Renal tubule regeneration after ischemic injury is coupled to the up-regulation and activation of cyclins and cyclin dependent kinases. Kidney Int 1997; 52: 706-714
39. Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543
40. Kitada K, Nakano D, Ohsaki H, et al. Hyperglycemia causes cellular senescence via a SGLT2-and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J Diabetes Complicat 2014; 28: 604-611
41. Megyesi J, Price PM, Tamayo E, et al. The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 1999; 96: 10830-10835
42. Ronconi E, Sagrinati C, Angelotti ML, et al. Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol 2009; 20: 322-332
43. Wanner N, Hartleben B, Herbach N, et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol 2014; 25: 707-716
44. Smeets B, Angelotti ML, Rizzo P, et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol 2009; 20: 2593-2603
45. Lasagni L, Ballerini L, Angelotti ML, et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells 2010; 28: 1674-1685
46. Johnson RJ, Raines EW, Floege J, et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992; 175: 1413-1416
47. Hugo C, Shankland SJ, Bowen-Pope DF, et al. Extraglomerular origin of the mesangial cell after injury. A new role of the juxtaglomerular apparatus. J Clin Invest 1997; 100: 786-794
48. Starke C, Betz H, Hickmann L, et al. Renin lineage cells repopulate the glomerular mesangium after injury. J Am Soc Nephrol 2015; 26: 48-54
49. Thomasova D, Mulay SR, Bruns H, et al. p53-independent roles of MDM2 in NF-kappaB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 2012; 14: 1097-1101
50. Hilliard S, Aboudehen K, Yao X, et al. Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching. Dev Biol 2011; 353: 354-366
51. Hilliard SA, Yao X, El-Dahr SS. Mdm2 is required for maintenance of the nephrogenic niche. Dev Biol 2014; 387: 1-14
52. Zhang Y, Xiong S, Li Q, et al. Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 2014; 233: 380-391
53. Allam R, Sayyed SG, Kulkarni OP, et al. Mdm2 promotes systemic lupus erythematosus and lupus nephritis. J Am Soc Nephrol 2011; 22: 2016-2027
54. Mulay SR, Thomasova D, Ryu M, et al. MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice. Kidney Int 2012; 81: 1199-1211
55. Hagemann JH, Thomasova D, Mulay SR, et al. Nrf2 signalling promotes ex vivo tubular epithelial cell survival and regeneration via murine double minute (MDM)-2. Nephrol Dial Transplant 2013; 28: 2028-2037
56. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J Cardiometab Syndr 2009; 4: E4-E9
57. Sakaguchi M, Isono M, Isshiki K, et al. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006; 340: 296-301
58. Benigni A, Morigi M, Rizzo P, et al. Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Am J Pathol 2011; 179: 628-638
59. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, et al. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int 2008; 73: 684-690
60. Molitoris BA, Dagher PC, Sandoval RMet al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20: 1754-1764
61. Zhou L, Fu P, Huang XR, et al. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 2010; 21: 31-41
62. Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009; 9: 831-841
63. Christophorou MA, Ringshausen I, Finch AJ, et al. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006; 443: 214-217
64. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737